Technology Bundle ID
TAB-2747

Recombinant Nucleic-Acid Based Flavivirus Nucleic Acids for Development of Vaccines and/or Sero-diagnostics

Linked ID
E-341-2013-0
Lead Inventors
Gwong-Jen Chang (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
ICs
CDC
CDC scientists have developed recombinant flavivirus nucleic acids for the generation of broad protective immunity against flaviviruses, as well as the development of sensitive serologic diagnostic tools. Mosquito borne viral encephalitis is often caused by a flavivirus, such as Japanese encephalitis virus, dengue virus or West Nile virus. Infection by these pathogens is often lethal to both humans and animals.

Specifically, these novel recombinant nucleic acids encode critical structural proteins of flaviviruses, such as yellow fever virus. The invention provides for a method of immunizing a subject against infection by a number of pathogenic flaviviruses. Furthermore, generated antigenic subviral particles can also serve as a tool for the development of specific, antibody detection-based flavivirus diagnostic assays.
Commercial Applications
  • Development of a broadly useful commercial vaccine for pathogenic flaviviruses
  • Insect-borne disease monitoring and surveillance programs
  • Generated antigen can be used for high-specificity serologic diagnostic assays
Competitive Advantages
  • In vivo animal studies demonstrate specific antibody generation and complete protection
  • Desired immune response provided by a single intramuscular injection in both murine and equine studies
  • Potential for vaccine use and the development of commercial flavivirus infection diagnostic assays and kits

Request More Info

Licensing Contact: